Concepedia

Soumil Parikh

SP

Statistics

Publications

5

Citations

319

H-Index

5

Active since

2015

Affiliations

Novartis (Switzerland)(Current)

Manchester Royal Eye Hospital

Soumil Parikh is an author at Novartis (Switzerland) specializing in pharmacotherapy, ocular pharmacology, and medicine.

Publications per year

2015–2021

5

Publications

5

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

Christian Prünte, Franck Fajnkuchen, Sajjad Mahmood et al. · British Journal of Ophthalmology · 2015 · 170 citations · Full text

, , +13

Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER

Michael Singer, Thomas A. Albini, András Seres et al. · Ophthalmology Retina · 2021 · 68 citations · Full text

, , +13

Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS study

Paul Mitchell, Tom Sheidow, Michel Eid Farah et al. · PLoS ONE · 2020 · 56 citations · Full text

, , +17

REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY

Adrian Koh, Timothy Y. Y. Lai, Wen Bin Wei et al. · Retina · 2019 · 13 citations · Full text

, , +17

Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study

Frank G. Holz, Angelo Maria Minnella, Raman Tuli et al. · PLoS ONE · 2020 · 12 citations · Full text

, , +13

1–5 of 5